Session Type
Meeting
Search Results for Anticoagulant
Abstract Number: 72
Hospital Medicine 2017, May 1-4, 2017; Las Vegas, Nev.
Background: Recent guidelines include aspirin as an option to prevent venous thromboembolism (VTE) in selected patients undergoing hip or knee replacement surgery. However, the efficacy of aspirin after arthroplasty has not been well-defined, particularly in more contemporary patient populations. Objective: To compare rates of post-operative VTE between patients who received aspirin-only versus anticoagulants after hip […]
Abstract Number: H8
SHM Converge 2022
Background: Role of vitamin K antagonist (VKA) or Direct Oral anticoagulation (DOAC) for non-valvular atrial fibrillation has widely been discussed. But the literature on anticoagulation therapy for patients with valvular atrial fibrillation (VAF) is limited. Aim of this meta-analysis was to evaluate the outcomes (stroke-vascular events and intracranial bleeding) following DOAC and VKA amongst patients […]
Abstract Number: 111
Hospital Medicine 2020, Virtual Competition
Background: Factor concentrates such as 4 factor-prothrombin complex concentrate (4F-PCC) are commonly used off-label as reversal agents in factor Xa inhibitor-associated bleeding events. However, there have been limited studies on the efficacy and safety of 4F-PCC use in these settings. We conducted a retrospective observational study of the use of 4F-PCC for major bleeding occurring […]
Abstract Number: 118
Hospital Medicine 2016, March 6-9, San Diego, Calif.
Background: Guidelines recommend pharmacologic venous thromboembolism (VTE) prophylaxis for high risk hospitalized medical patients that do not have an elevated bleeding risk. A systematic review of randomized trials estimates the overall bleeding risk with pharmacologic prophylaxis to be low, at 1/1000 (0.1%). However, it is unclear if the bleeding events were related to pharmacologic prophylaxis […]
Abstract Number: 129
Hospital Medicine 2018; April 8-11; Orlando, Fla.
Background: Over 6 million people in the US have a diagnosis of atrial fibrillation. Given the increased risk for stroke and systemic embolism, many patients are treated with direct oral anticoagulants (DOACs) to reduce their risk. In the major trials comparing to DOACs to warfarin for stroke and systemic embolism prevention in atrial fibrillation, DOACs […]
Abstract Number: 129
Hospital Medicine 2020, Virtual Competition
Background: Cancer-associated thrombosis (CAT) is a common complication in patients with malignancy. Management of venous thromboembolism (VTE), in these patients, is challenging due to the high risk of recurrence and inherent risk of bleeding in this population. Direct oral anticoagulants (DOACs) have emerged as a treatment options for CAT. As yet there have not been […]
Abstract Number: 145
Hospital Medicine 2018; April 8-11; Orlando, Fla.
Background: Venous thromboembolism (VTE) in hospitalized medically ill patients is a leading preventable cause of morbidity and mortality in the United States. About half of VTE events occur following discontinuation of standard-duration in-hospital prophylaxis and hospital discharge. The APEX study evaluated Betrixaban for in-hospital to home VTE prophylaxis and is the first FDA approved anticoagulant […]
Abstract Number: 160
Hospital Medicine 2016, March 6-9, San Diego, Calif.
Background: Oral anticoagulation is effective for reduction of risk for stroke and systemic embolism in patients with nonvalvular atrial fibrillation, but there may be uncertainty about how to manage anticoagulation in and following an emergency procedure or after treatment of hemorrhage. In case of an emergency, anticoagulation would ideally be immediately and completely reversed, bringing […]
Abstract Number: 211
Hospital Medicine 2019, March 24-27, National Harbor, Md.
Background: Hospitalized patients receiving direct oral anticoagulants (DOACs) sometimes require bridging with unfractionated heparin (UFH). Monitoring UFH with anti-Xa assays has been shown to correlate with better outcomes. However, DOACs interfere with anti-Xa assays resulting in inappropriate UFH dose adjustments that can negatively impact patient care. In 2015, we deployed an electronic health record (EHR) […]
Abstract Number: 259
Hospital Medicine 2019, March 24-27, National Harbor, Md.
Background: Perioperative management of anticoagulant in mechanical valve patients is challenging, Current recommendations focus on management in patients undergoing elective surgery, while the data in patients hospitalized for emergency/urgency non-cardiac surgery is limited. We aimed to identify thromboembolic and bleeding events after anticoagulant interruption in patients with mechanical heart valves hospitalized for emergency/urgent non-cardiac surgery. […]